ESC Professional Premium Access

Differences in the prevalence of cardiovascular toxicity in a cohort of female breast cancer patients according to the different cardiotoxicity definitions

Congress Presentation

About the speaker

Doctor Javier Herrera

University Hospital Queen Sofia, Cordoba (Spain)
1 presentation
0 follower

7 more presentations in this session

The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients

Speaker: Doctor S. Maragkoudakis (Chania, GR)


SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

Speaker: Doctor N. Maurea (Naples, IT)


SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

Speaker: Doctor N. Maurea (Naples, IT)


The use of high sensitivity troponin T as a biomarker of anthracycline cardiotoxicity

Speaker: Doctor C. Bannister (London, GB)


The utility of the HFA-ICOS cardiotoxicity risk assessment tool for HER2-targeted cancer therapies in patients with metastatic breast cancer: from theory to clinical practice.

Speaker: Doctor D. Leocachin Parra (Mexico City, MX)


Access the full session

Cardiotoxicity: mechanisms, biomarkers, and treatment

Speakers: Doctor J. Herrera, Doctor S. Maragkoudakis, Doctor N. Maurea, Doctor N. Maurea, Doctor C. Bannister...

About the event


ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

ESC 365 is supported by